Explore

Semaglutide Extends Lifespan and Slows Aging in Healthy Mice, NIH-Funded Study Reveals

Semaglutide Extends Lifespan and Slows Aging in Healthy Mice, NIH-Funded Study Reveals

An NIH-funded study has demonstrated that semaglutide, a GLP-1 drug, extended the lifespan and slowed physiological aging in healthy older mice. Researchers at the University of California, Berkeley administered semaglutide to 20-month-old female mice for three months, observing improvements in muscle and cognitive function compared to a control group. Gene expression analysis revealed a reduction in hallmarks of natural aging, such as increased inflammation and decreased regenerative capacity. Another group of mice treated until the end of life experienced a median lifespan nearly 100 days longer than untreated mice. The study also compared semaglutide's effects to calorie restriction, finding that while both showed parallels, semaglutide-treated mice exhibited superior exploratory behavior, spatial memory, and blood-sugar maintenance, suggesting a potential biological pathway independent of calorie reduction.

GLP-1 Drug Semaglutide Shows Promise in Slowing Aging and Extending Lifespan in Mice

GLP-1 Drug Semaglutide Shows Promise in Slowing Aging and Extending Lifespan in Mice

A new study published in Nature indicates that the GLP-1 drug semaglutide, commonly used for diabetes and obesity treatment, can slow physiological aging and extend the lifespan of older, healthy mice. Researchers administered semaglutide to 20-month-old female C57BL/6 mice for three months, observing improvements in physiological function, attenuation of aging hallmarks, and modulation of nutrient sensors and genetic regulators of aging. Another group of mice treated until the end of their lives experienced a median lifespan nearly 100 days longer than untreated mice. The study compared the effects of semaglutide to caloric restriction, finding that while both showed anti-aging benefits, semaglutide-treated mice surpassed baseline levels in exploratory behavior, spatial memory, and blood-sugar maintenance, and maintained a largely unchanged metabolic rate, unlike the calorie-restricted group. This suggests that GLP-1 drugs may activate a biological pathway independent of calorie restriction.

GLP-1 Drugs Show Potential to Extend Lifespan and Healthspan in Mice, Suggesting Broader Applications Beyond Weight Loss

GLP-1 Drugs Show Potential to Extend Lifespan and Healthspan in Mice, Suggesting Broader Applications Beyond Weight Loss

A new study indicates that GLP-1 drugs, such as those found in Ozempic and Wegovy, may offer significant longevity benefits. Researchers compared mice treated with semaglutide (the active ingredient in these drugs) to a control group and observed improvements in blood markers, appearance, and behavior. Most notably, the mice receiving the drug lived approximately 100 days longer, representing a 12% increase in lifespan. This finding suggests that GLP-1s could influence various biological changes associated with aging, including chronic inflammation, DNA damage, cellular senescence, and mitochondrial dysfunction. The study also found that GLP-1-treated mice exhibited better muscle and cognitive function. While calorie restriction is known to extend life, the GLP-1 drugs demonstrated additional benefits, particularly in exploratory behavior, spatial memory, and blood sugar regulation, suggesting a biological pathway independent of calorie reduction. These results, if translatable to humans, could imply an ad...

Semaglutide Shows Potential in Slowing Biological Aging, According to New Research

Semaglutide Shows Potential in Slowing Biological Aging, According to New Research

Recent studies suggest that semaglutide, a GLP-1 injection, may slow down biological aging. A study involving 84 participants indicated that those receiving semaglutide experienced a 9 percent slowdown in biological aging compared to a placebo group. This slowdown was measured using epigenetic clocks, which analyze age-related DNA methylation patterns to understand how cells in organs like the brain, heart, liver, and kidneys are reprogrammed over time. Additionally, nearly 49 percent of participants showed longer telomeres, protective caps on DNA that typically shorten with age. Researchers, including Michael Corley, PhD, associate professor at the UC San Diego School of Medicine, emphasize that these findings do not mean semaglutide reverses aging but rather signals a potential to slow down some biological processes associated with it. Another pilot study on 41 individuals with HIV and fatty liver disease also observed a slower rate of biological aging in 42 percent of participants and longer telomeres i...

NYU Langone Health Study Links GLP-1 Drugs to Increased Hair Loss Risk in Genetically Predisposed Men

NYU Langone Health Study Links GLP-1 Drugs to Increased Hair Loss Risk in Genetically Predisposed Men

A new study led by researchers at NYU Langone Health indicates that men with a genetic predisposition for androgenetic alopecia, the most common form of hair loss, face an additional 7% risk of hair loss when using GLP-1 medications such as Ozempic, Wegovy, and Zepbound. These drugs are prescribed for type 2 diabetes and obesity. The study, published online on September 3 in the Journal of Investigative Dermatology, focused on the GLP1R gene, which is associated with increased levels of glucagon-like peptide-1 (GLP-1) receptor proteins. Researchers compared the presence of GLP1R genes with genes found in men with androgenetic alopecia, an inherited pattern baldness. While rapid weight loss has previously been cited as a cause for hair thinning among GLP-1 users, this study provides the first genetic link, suggesting a biological connection. The analysis accounted for other known risk factors for hair loss, including hypertension, insulin resistance, and lowered testosterone levels, yet the 7% increased ris...

FDA Issues Warnings to Online Sellers for Illicit Weight Loss Peptides, Citing Public Health Risks

FDA Issues Warnings to Online Sellers for Illicit Weight Loss Peptides, Citing Public Health Risks

The U.S. Food and Drug Administration (FDA) has intensified its crackdown on the illegal online trade of unapproved peptides, issuing warning letters to five U.S.-headquartered companies: Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations LLC dba Tex Peptides. These companies are accused of violating FDA regulations by selling new peptide-based drugs that lack approval and regulation. The primary concern revolves around the sale of illicit weight loss products, including versions of Eli Lilly's retatrutide, which is not yet approved globally, and Novo Nordisk's semaglutide, marketed as Wegovy and Ozempic. Beyond weight loss drugs, these sellers also offer unapproved therapeutics for growth hormone release, muscle boosting, and libido enhancement. The FDA asserts that despite claims of these products being for 'laboratory research and development purposes only' and 'not for veterinary or human use,' evidence from the companies' websites indicates they are in...

Diet Quality Linked to Epigenetic Aging Pace in German Adults, Study Finds

Diet Quality Linked to Epigenetic Aging Pace in German Adults, Study Finds

A study involving 6,470 German adults has found that adherence to various healthy diet patterns is associated with a slower pace of biological aging, as measured by DNA methylation. Researchers at the German Centre for Neurodegenerative Diseases assessed participants against ten established diet quality indexes, including the Mediterranean Diet Score, DASH, and the MIND diet, and compared these scores to epigenetic aging measures like GrimAge acceleration, PhenoAge acceleration, and DunedinPACE. The findings, replicated in a separate cohort of 1,034 adults, indicated that all ten diet quality scores were significantly linked to DunedinPACE, with eight healthy patterns correlating with slower aging and two unhealthy ones with faster aging. While the specific diets showed minimal overlap in the individual methylation sites they affected, over 70% of the involved biological pathways converged, primarily governing cell structure, signaling, and metabolism. The DASH and Nordic diets were consistently linked to ...

Looking for cheaper GLP-1 medications? This program starts at $150

Looking for cheaper GLP-1 medications? This program starts at $150

Fridays Health offers access to semaglutide, tirzepatide and brand-name GLP-1 medications. Here's how much it costs, what's included and how to save.

NIH-Funded Study Shows GLP-1 Treatment Extends Lifespan in Older Mice

NIH-Funded Study Shows GLP-1 Treatment Extends Lifespan in Older Mice

A National Institutes of Health (NIH)-funded study has revealed that the GLP-1 drug semaglutide extended the lifespan of older, healthy mice. Researchers at the University of California, Berkeley, administered semaglutide to 20-month-old female mice for three months, observing improvements in muscle and cognitive function. Gene expression analysis indicated a reduction in hallmarks of natural aging, such as increased inflammation and decreased regenerative capacity. Another group of mice treated until the end of life experienced a median lifespan nearly 100 days longer than untreated mice. The study compared the effects of semaglutide with calorie restriction, finding that the drug mimicked the anti-aging benefits of reduced food intake and offered additional advantages in certain areas. For instance, semaglutide-treated mice showed enhanced exploratory behavior, spatial memory, and blood-sugar maintenance, surpassing baseline levels. The study suggests that GLP-1 drugs may slow physiological aging itself,...

'Microdosing' GLP-1s can shed pounds, but here are the dangers

'Microdosing' GLP-1s can shed pounds, but here are the dangers

New research sheds some light on potential dangers and benefits of taking smaller-than-recommended doses of the popular medications Wegovy, Zepbound.

Semaglutide Demonstrates Significant Weight Loss and Anti-Inflammatory Benefits in Non-Diabetic Adults

Semaglutide Demonstrates Significant Weight Loss and Anti-Inflammatory Benefits in Non-Diabetic Adults

A recent systematic review and meta-analysis, published in the International Journal of Obesity, has confirmed the significant efficacy and safety profile of subcutaneous semaglutide for weight management in adults with overweight or obesity who do not have diabetes. The analysis pooled data from nine randomized controlled trials involving 6,239 participants, with 4,203 receiving semaglutide and 2,036 receiving a placebo. The findings revealed that semaglutide was associated with a 12.04-percentage-point greater reduction in body weight, a 9.36 cm greater reduction in waist circumference, and a 40.90-percentage-point greater reduction in C-reactive protein (CRP) compared to placebo. These results highlight semaglutide's substantial improvements in weight-related outcomes and its anti-inflammatory effects.

U.S. Department of Health and Human Services Funds Research to Validate 'Intrinsic Capacity' as Key Healthspan Metric

U.S. Department of Health and Human Services Funds Research to Validate 'Intrinsic Capacity' as Key Healthspan Metric

The Advanced Research Projects Agency for Health (ARPA-H), an entity within the U.S. Department of Health and Human Services, has initiated a new research program focused on 'intrinsic capacity' as a measure of healthy aging. Intrinsic capacity, formally defined by the World Health Organization in 2015, is a holistic metric encompassing an individual's physical and mental capabilities, including cognition, locomotion, sensory capacity, psychological well-being, and vitality. The program's primary goal is to validate intrinsic capacity as a reliable indicator for assessing the effectiveness of interventions aimed at extending healthspan. Currently, the U.S. Food and Drug Administration (FDA) does not recognize aging as a disease, which presents a significant hurdle for approving drugs designed to alter the aging process. Researchers believe that demonstrating a clear link between intrinsic capacity and health outcomes could provide a pathway for FDA approval of longevity-focused medications. A similar study...